These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19163828)

  • 1. Understanding virulence mechanisms in M. tuberculosis infection via a circuit-based simulation framework.
    May E; Leitao A; Faulon JL; Joo J; Misra M; Oprea TI
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():4953-5. PubMed ID: 19163828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis.
    Ehlers S
    Infection; 2009 Apr; 37(2):87-95. PubMed ID: 19308316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent and dormant tubercle bacilli and latent tuberculosis.
    Zhang Y
    Front Biosci; 2004 May; 9():1136-56. PubMed ID: 14977534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Mycobacterium tuberculosis infection on adipocyte physiology.
    Ayyappan JP; Vinnard C; Subbian S; Nagajyothi JF
    Microbes Infect; 2018 Feb; 20(2):81-88. PubMed ID: 29109018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Capacity of
    Kurthkoti K; Amin H; Marakalala MJ; Ghanny S; Subbian S; Sakatos A; Livny J; Fortune SM; Berney M; Rodriguez GM
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host-pathogen redox dynamics modulate Mycobacterium tuberculosis pathogenesis.
    Pacl HT; Reddy VP; Saini V; Chinta KC; Steyn AJC
    Pathog Dis; 2018 Jul; 76(5):. PubMed ID: 29873719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease.
    Cardona PJ
    Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):7-14. PubMed ID: 20049645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mathematical representation of the development of Mycobacterium tuberculosis active, latent and dormant stages.
    Magombedze G; Mulder N
    J Theor Biol; 2012 Jan; 292():44-59. PubMed ID: 21968442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of glycans and glycoproteins in disease development by Mycobacterium tuberculosis.
    Sonawane A; Mohanty S; Jagannathan L; Bekolay A; Banerjee S
    Crit Rev Microbiol; 2012 Aug; 38(3):250-66. PubMed ID: 22324751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches.
    Borah K; Xu Y; McFadden J
    Front Immunol; 2021; 12():762315. PubMed ID: 34795672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.
    Coppola M; Ottenhoff TH
    Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
    Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
    Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the potential impact of host population survival on the evolution of M. tuberculosis latency.
    Zheng N; Whalen CC; Handel A
    PLoS One; 2014; 9(8):e105721. PubMed ID: 25157958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection.
    Salgame P
    Curr Opin Immunol; 2005 Aug; 17(4):374-80. PubMed ID: 15963709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium tuberculosis infection of host cells in space and time.
    Bussi C; Gutierrez MG
    FEMS Microbiol Rev; 2019 Jul; 43(4):341-361. PubMed ID: 30916769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mathematical model of the initial interaction between Mycobacterium tuberculosis and macrophages.
    Pienaar E; Lerm M
    J Theor Biol; 2014 Feb; 342():23-32. PubMed ID: 24112967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.